Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes

详细信息    查看全文

• 作者：Qi-qiang Long (1) (2)
  Yong-xiang Yi (3)
  Jie Qiu (2)
  Chuan-jun Xu (4)
  Pei-lin Huang (1)
  
• 关键词：Fatty acid synthase (FASN) ; Colorectal cancer ; Enzyme ; linked immunosorbent assay (ELISA)
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：35
• 期：4
• 页码：3855-3859
• 全文大小：216 KB
• 参考文献：1. Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res. 2009;50:138-3. CrossRef
  2. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006;66(12):5977-0. CrossRef
  3. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem. 2004;91(1):47-3. CrossRef
  4. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996;77:474-2. CrossRef
  5. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W, Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene. 2000;19:5173-1. CrossRef
  6. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel S. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. J Cancer Res. 2007;67:1262-. CrossRef
  7. Kuhajda FP. Fatty acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16(3):202-. CrossRef
  8. Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP, et al. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle. 2008;7(19):3021-. CrossRef
  9. Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137-0. CrossRef
  10. Silva SD, Cunha IW, Nishimoto IN, et al. Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas. Oral Oncol. 2009;02(004):1368-3.
  11. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26(35):5713-0. CrossRef
  12. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Scerensen FB. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol. 1995;176:343-2. CrossRef
  13. Kuhajda FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91:6379-3. CrossRef
  14. Huang PL, Zhu SN, Shi Lun L, et al. Inhibitor of fatty acid synthase induced apoptosis in human colonic cancer cells. World J Gastroenterol. 2000;6(2):295-.
  15. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res. 2009;53(9):1156-5. CrossRef
  16. Wang Y, Kuhajda FP, Lori J, Sokoll, et al. Two-site ELISA for the quantitative determination of fatty acid synthase. Clin Chim Acta. 2001;304:107-5. CrossRef
  17. Wang Y, Kuhajda FP, Li JN, et al. Fatty acid synthase expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 2001;167:99-04. CrossRef
  18. Walter K, Hong S-M, Nyhan S, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2380-. CrossRef
  19. Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, et al. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncology. 2009;35:1369-6.
  20. Notarnicola M, Tutino V, Calvani M, et al. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J Gastrointest Cancer. 2012;43:508-1. CrossRef
  21. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763-7. CrossRef
  22. Alli PM, Pinn ML, Jaffee EM, et al. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene. 2005;24:39-6. CrossRef
  23. Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070-. CrossRef
  24. Relat J, Blancafort A, Oliveras G, et al. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer. 2012;12:280. CrossRef
  25. Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat. 2004;84:183-5. CrossRef
  
• 作者单位：Qi-qiang Long (1) (2)
  Yong-xiang Yi (3)
  Jie Qiu (2)
  Chuan-jun Xu (4)
  Pei-lin Huang (1)
  
  1. Department of Internal Medicine, Medical School of Southeast University, Southeast University, DingjiaQiao 87, Nanjing, 210009, People’s Republic of China
  2. Department of Internal Medicine, The Second Affiliated Hospital of Southeast University, Zhongfu Road 1, Nanjing, 210003, People’s Republic of China
  3. Department of Surgical Medicine, The Second Affiliated Hospital of Southeast University, Zhongfu Road 1, Nanjing, 210003, People’s Republic of China
  4. Department of Imaging Medicine, The Second Affiliated Hospital of Southeast University, Zhongfu Road 1, Nanjing, 210003, People’s Republic of China
  
• ISSN：1423-0380

文摘

Fatty acid synthase (FASN) is a common phenotype to many kinds of human cancers, such as those of the breast, ovary, pancreas, prostate, colon, and so on. Increased FASN levels have been detected in the serum of the patients with breast and pancreatic cancers. The relationship between the FASN level in serum and the clinicopathological characteristics of colorectal cancer is investigated in this study. FASN levels in serum were examined with enzyme-linked immunosorbent assay (ELISA) in 74 patients with colorectal cancer and 40 healthy persons. Pathological and clinical factors associated with FASN concentrations in serum were investigated and analyzed by statistical analysis. The FASN level in colorectal cancer patients-serum is significantly higher than that in healthy persons-serum. FASN levels in the serum of colorectal cancer patients are associated with tumor extent, lymph node metabasis status, distant metastasis, and tumor clinical stage. The 5-year overall survival rate and 5-year disease-free survival rate among patients with low FASN levels in serum are significantly higher than those among patients with high FASN levels in serum (log-rank P--.003). The high FASN level in serum is a promising independent predictor of colorectal cancers with advanced phases, late clinical stages, and shorter survival. These results suggest that FASN concentration in serum may be a potential and useful tumor marker.